Cargando…

mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new...

Descripción completa

Detalles Bibliográficos
Autores principales:	BU, CHIWEN, ZHAO, LIGANG, WANG, LISHAN, YU, ZEQIAN, ZHOU, JIAHUA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tech Science Press 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319595/ https://www.ncbi.nlm.nih.gov/pubmed/37415733 http://dx.doi.org/10.32604/or.2023.029309

Ejemplares similares

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)

Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
por: Wang, Quan, et al.
Publicado: (2013)

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015)

The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017)

Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC
por: Hong, Chen, et al.
Publicado: (2022)

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
por: Du, Heng, et al.
Publicado: (2023)

mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)

LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
por: Yang, Jin Young, et al.
Publicado: (2019)

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022)

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015)

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
por: Wolin, Edward, et al.
Publicado: (2019)

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
por: Burnett, G. Leslie, et al.
Publicado: (2022)

mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors
por: Zhu, Ping Jun, et al.
Publicado: (2018)

PRL-3 activates mTORC1 in Cancer Progression
por: Ye, Zu, et al.
Publicado: (2015)

Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors
por: Lee, Dongjun, et al.
Publicado: (2014)

RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
por: Weinberg, Mark A.
Publicado: (2016)

Glutaminolysis feeds mTORC1
por: Durán, Raúl V., et al.
Publicado: (2012)

Regulation of adiposity by mTORC1
por: Magdalon, Juliana, et al.
Publicado: (2017)

Regulation of mTORC2 Signaling
por: Fu, Wenxiang, et al.
Publicado: (2020)

mTORC2 Steals the Spotlight
por: Jansen, Laura A.
Publicado: (2020)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer
por: Brown, Wells S., et al.
Publicado: (2020)

Regulation of Autophagy through TORC1 and mTORC1
por: Noda, Takeshi
Publicado: (2017)

Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry
por: Rogers-Broadway, Karly-Rai, et al.
Publicado: (2019)

Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTorc2 activation
por: Rodriguez-Vargas, José-Manuel, et al.
Publicado: (2020)

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
por: Zhang, Hao, et al.
Publicado: (2013)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
por: Mateo, Joaquin, et al.
Publicado: (2016)

mTORC2 dictates Warburg effect and drug resistance
por: Masui, Kenta, et al.
Publicado: (2014)

Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
por: Faes, Seraina, et al.
Publicado: (2016)

mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
por: Walters, Hannah E., et al.
Publicado: (2018)

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
por: Abdallah, Chadi G., et al.
Publicado: (2020)

Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells
por: Sandoval, Jose A., et al.
Publicado: (2020)

Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication
por: Kuss-Duerkop, Sharon K., et al.
Publicado: (2017)

Differential regulation of mTORC1 and mTORC2 is critical for 8-Br-cAMP-induced decidualization
por: Baek, Mi-Ock, et al.
Publicado: (2018)

Genetic inactivation of mTORC1 or mTORC2 in neurons reveals distinct functions in glutamatergic synaptic transmission
por: McCabe, Matthew P, et al.
Publicado: (2020)

LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control
por: Gan, Wenjian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qm8frvdobmfuvf6cvdqemg6blu